Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma.
Standard
Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. / Atanackovic, Djordje; Panse, Jens; Hildebrandt, York; Jadczak, Adam; Kobold, Sebastian; Cao, Yanran; Templin, Julia; Meyer, Sabrina; Reinhard, Henrike; Bartels, Katrin; Lajmi, Nesrine; Zander, Axel R.; Marx, Andreas; Bokemeyer, Carsten; Kröger, Nicolaus.
In: HAEMATOLOGICA, Vol. 96, No. 10, 10, 2011, p. 1512-1520.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma.
AU - Atanackovic, Djordje
AU - Panse, Jens
AU - Hildebrandt, York
AU - Jadczak, Adam
AU - Kobold, Sebastian
AU - Cao, Yanran
AU - Templin, Julia
AU - Meyer, Sabrina
AU - Reinhard, Henrike
AU - Bartels, Katrin
AU - Lajmi, Nesrine
AU - Zander, Axel R.
AU - Marx, Andreas
AU - Bokemeyer, Carsten
AU - Kröger, Nicolaus
PY - 2011
Y1 - 2011
N2 - To date, multiple myeloma remains an incurable malignancy due to the persistence of minimal residual disease in the bone marrow. In this setting, monoclonal antibodies against myeloma-specific cell surface antigens represent a promising therapeutic approach, which is however hampered by a lack of appropriate target structures expressed across all pathogenic myeloma cell populations. We, therefore, investigated functionally relevant immunoreceptors specifically associated with myeloma cells as well as their clonogenic precursors.
AB - To date, multiple myeloma remains an incurable malignancy due to the persistence of minimal residual disease in the bone marrow. In this setting, monoclonal antibodies against myeloma-specific cell surface antigens represent a promising therapeutic approach, which is however hampered by a lack of appropriate target structures expressed across all pathogenic myeloma cell populations. We, therefore, investigated functionally relevant immunoreceptors specifically associated with myeloma cells as well as their clonogenic precursors.
KW - Humans
KW - Cell Line, Tumor
KW - Gene Expression Regulation, Neoplastic
KW - Gene Expression
KW - Gene Silencing
KW - Antineoplastic Agents/pharmacology
KW - Antigens, CD/genetics/metabolism
KW - Cell Survival/drug effects/genetics
KW - Cytotoxicity, Immunologic/drug effects/genetics
KW - Lymphocyte Subsets/metabolism
KW - Multiple Myeloma/diagnosis/genetics/metabolism/therapy
KW - Neoplastic Stem Cells/metabolism
KW - Plasma Cells/metabolism/pathology
KW - Humans
KW - Cell Line, Tumor
KW - Gene Expression Regulation, Neoplastic
KW - Gene Expression
KW - Gene Silencing
KW - Antineoplastic Agents/pharmacology
KW - Antigens, CD/genetics/metabolism
KW - Cell Survival/drug effects/genetics
KW - Cytotoxicity, Immunologic/drug effects/genetics
KW - Lymphocyte Subsets/metabolism
KW - Multiple Myeloma/diagnosis/genetics/metabolism/therapy
KW - Neoplastic Stem Cells/metabolism
KW - Plasma Cells/metabolism/pathology
U2 - 10.3324/haematol.2010.036814
DO - 10.3324/haematol.2010.036814
M3 - SCORING: Journal article
VL - 96
SP - 1512
EP - 1520
JO - HAEMATOLOGICA
JF - HAEMATOLOGICA
SN - 0390-6078
IS - 10
M1 - 10
ER -